Talk:Insulin analog

message: This link (http://www.pslgroup.com/dg/1cdef6.htm) contradicts Lantus's availability as occuring in 2003.  Also it might be good to specify that this is US availability -- other countries may adopt earlier or later. 192.75.95.127 22:45, 9 March 2007 (UTC)
thread_title: Lantus availablility

message: Is NPH considered an "insulin analog" the way the drugs listed on this page are?  I get the impression that the insulin molecule itself isn't modified, it's just mixed with protamine.  Guy Harris 23:39, 5 September 2007 (UTC)
thread_title:  NPH? 

message: There is much waffle in the second paragraph, it could be reduced to the first couple of sentences, or lost entirely Andywhatever (talk) 20:19, 29 March 2014 (UTC)
thread_title:  Criticism 

message: I would like to suggest two corrections in the section about Insulin_analogue#Insulin_degludec on the Insulin_analogue page. 
The article currently states that insulin degludec is being developed. It is already approved and marketed in Europe and other countries, so I suggest to delete 'being' in that sentence.  
The article also states that insulin degludec may be injected thrice per week instead of once per day. It is currently approved for once per day, and the reference to the suggestion, that it may be injected thrice per week, is an old article from October 2010. 
Can anyone help me correct this:
delete the first part about thrice per week to keep it aligned with the description approved by The European Medicines Agency.
The EMA page about insulin degludec as external 3rd party source for both corrections.http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002498/human_med_001609.jsp&mid=WC0b01ac058001d124
Will anyone be able to review this and make the appropriate corrections?
:Kofod (talk) Kasper Kofod 13:06, 14 April 2014 (UTC)
replies: text: , I've removed the  tag you've placed, as it is mainly to be used when someone is unsure of how to edit wikipedia. It is not to be used to create discussion on article editing. Cheers, Primefac (talk) 16:06, 26 September 2014 (UTC)
thread_title:  Corrections to the section about insulin degludec 

message: First off, I'm an endocrinologist by profession so this field is my expertise. There are major errors in this Wikipedia entry because it includes insulins that are NOT analogs being listed as analogs. To be an insulin analog, the fundamental molecular structure of the insulin must have been deliberately altered to modify the insulin's dynamics (absorption, duration of action, etc.). In particular this involves modifying the amino acid sequence of the insulin (e.g. lispro) or adding something to the amino acid chain (e.g. myristic acid in detemir). 
In this regard:
1. Animal insulins -- are NOT analogs. They are simply insulins of non-human origin and therefore differ from human insulin by one or a few amino acids. 
2. NPH (neutral protamine Hagedorn) insulin -- is NOT an analog. It's human insulin that's mixed with protamine to decrease its solubility and therefore prolong the action. The fundamental structure of the insulin is unaltered.
When "insulin analog" is used in medical literature it only refers to the short-acting analogs lispro, aspart and glulisine, the older long-acting analogs detemir and glargine, and the newest long-acting analog degludec. Therefore the entries for "fast acting" should only have lispro, aspart and glulisine while "long acting" should have glargine, detemir, and degludec. If the purpose of putting NPH and animal insulins in the article is for comparison purposes then they can be kept BUT they should moved to a separate section. The current categorization is highly misleading and implies that NPH and animal insulins are analogs when in fact they aren't.
Hwi Noree (talk) 18:51, 12 February 2015 (UTC)
thread_title:  Errors